Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...
FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia. Immune ...
During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...
Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their discussion on Lambert-Eaton myasthenic syndrome (LEMS) in patients with ...
Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...
Months ahead of the target action date, the FDA recently approved the pan-RAS inhibitor daraxonrasib (Rasonque) for patients ...
Celcuity seeks FDA expansion for gedatolisib combos in PIK3CA-mutant HR+/HER2- metastatic breast cancer, after VIKTORIA-1 ...
The FDA has granted fast track designation (FTD) to ERAS-0015, an oral pan-RAS molecular glue, clearing an expedited ...
The assays are now approved to assess HER2 status in gastric, gastroesophageal junction, and esophageal adenocarcinoma.
In the GESTALT feasibility and safety trial, GammaTile reduced rapid early progression to 6% vs a historical 50% to 80%, with ...
The American Society of Clinical Oncology (ASCO) has released its inaugural guideline on the systemic treatment of recurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results